Mainz Biomed N.V. Regains Compliance with Nasdaq Capital Market Listing Requirements
Mainz Biomed (NASDAQ:MYNZ) has successfully regained full compliance with Nasdaq Capital Market listing requirements. The company received formal notice from Nasdaq on January 23, 2025, confirming its compliance with the minimum stockholders' equity requirement under Listing Rule 5550(b)(1). This follows their previous confirmation of compliance with the minimum bid price requirement under Rule 5550(a)(2). As a result, MYNZ will maintain its listing and continue trading on the Nasdaq Capital Market.
Mainz Biomed (NASDAQ:MYNZ) ha ripristinato con successo la piena conformità ai requisiti di quotazione del Nasdaq Capital Market. L'azienda ha ricevuto una comunicazione formale dal Nasdaq il 23 gennaio 2025, confermando la propria conformità al requisito minimo di patrimonio netto degli azionisti ai sensi della Regola di Quotazione 5550(b)(1). Questo segue la loro precedente conferma di conformità con il requisito di prezzo minimo di offerta ai sensi della Regola 5550(a)(2). Di conseguenza, MYNZ manterrà la sua quotazione e continuerà a essere scambiata sul Nasdaq Capital Market.
Mainz Biomed (NASDAQ:MYNZ) ha recuperado con éxito el cumplimiento completo de los requisitos de cotización del Nasdaq Capital Market. La compañía recibió un aviso formal de Nasdaq el 23 de enero de 2025, confirmando su cumplimiento con el requisito mínimo de capital de los accionistas bajo la Regla de Cotización 5550(b)(1). Esto sigue a su confirmación previa de cumplimiento del requisito del precio mínimo de oferta bajo la Regla 5550(a)(2). Como resultado, MYNZ mantendrá su cotización y continuará siendo negociada en el Nasdaq Capital Market.
Mainz Biomed (NASDAQ:MYNZ)는 Nasdaq Capital Market의 상장 요구사항을 성공적으로 완전하게 준수했습니다. 회사는 2025년 1월 23일 Nasdaq으로부터 주주 자본 최소 요건에 대한 준수를 확인하는 공식 통지를 받았습니다(상장 규칙 5550(b)(1) 기준). 이는 가격 제안 최소 요구 사항에 대한 준수 확인(규칙 5550(a)(2) 기준)을 따릅니다. 결과적으로 MYNZ는 상장을 유지하고 Nasdaq Capital Market에서 계속 거래될 것입니다.
Mainz Biomed (NASDAQ:MYNZ) a réussi à rétablir pleinement sa conformité aux exigences de cotation du Nasdaq Capital Market. La société a reçu un avis formel de Nasdaq le 23 janvier 2025, confirmant sa conformité à l'exigence de capital des actionnaires sous la Règle de Cotation 5550(b)(1). Cela fait suite à leur précédente confirmation de conformité avec l'exigence de prix d'offre minimum selon la Règle 5550(a)(2). En conséquence, MYNZ maintiendra sa cotation et continuera à être négocié sur le Nasdaq Capital Market.
Mainz Biomed (NASDAQ:MYNZ) hat erfolgreich die vollständige Einhaltung der Anforderungen des Nasdaq Capital Market zur Listung wiederhergestellt. Das Unternehmen erhielt am 23. Januar 2025 eine formelle Mitteilung von Nasdaq, die seine Einhaltung der Mindestkapitalanforderung für Aktionäre gemäß Listing Rule 5550(b)(1) bestätigte. Dies folgt auf die vorherige Bestätigung der Einhaltung des Mindestkursangebotes gemäß Regel 5550(a)(2). Infolgedessen wird MYNZ seine Listung beibehalten und weiterhin am Nasdaq Capital Market gehandelt werden.
- Regained full compliance with Nasdaq listing requirements
- Secured continued listing on Nasdaq Capital Market
- None.
Insights
The restoration of Nasdaq compliance represents a significant milestone for Mainz Biomed, effectively removing a major overhang that could have severely impacted its market position and accessibility to capital markets. This development carries several critical implications for investors:
Market Access & Liquidity Benefits: Maintaining Nasdaq listing status ensures continued access to a broader investor base, particularly institutional investors who often have mandate restrictions preventing them from investing in over-the-counter stocks. This preserved listing status helps maintain trading liquidity and price stability.
Financial Stability Indicators: Meeting the stockholders' equity requirement demonstrates improved financial health and operational stability. This is particularly relevant for a molecular genetics diagnostic company where capital requirements for research and development are substantial.
Strategic Positioning: Retaining Nasdaq listing status preserves Mainz Biomed's ability to raise capital through traditional equity offerings, which is important for a company in the diagnostic sector where continuous investment in product development and clinical trials is essential. The maintained listing also positions the company more favorably for potential strategic partnerships or future capital raising initiatives.
Risk Mitigation: This compliance achievement eliminates the immediate risk of delisting, which could have triggered forced selling by institutional investors and potential loan covenant issues. It also removes the distraction of compliance concerns, allowing management to focus fully on operational execution and business development.
BERKELEY, Calif. and MAINZ, Germany, Jan. 27, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed NV (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today that on January 23, 2025, the Company received formal notice from The Nasdaq Stock Market LLC (“Nasdaq”) confirming that it has regained compliance with the minimum stockholders’ equity requirement for continued listing on the Nasdaq Capital Market set forth in Listing Rule 5550(b)(1). Mainz Biomed had previously received confirmation that it had regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2). Mainz Biomed is now in full compliance with all Nasdaq continued listing requirements and will continue to be listed and traded on The Nasdaq Capital Market.
Please follow us to stay up to date:
LinkedIn
X (Previously Twitter)
Facebook
About Mainz Biomed NV
Mainz Biomed develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The Company’s flagship product is ColoAlert®, an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer. ColoAlert® is marketed across Europe and the United Arab Emirates. The Company is currently running a pivotal FDA clinical study for US regulatory approval. Mainz Biomed’s product candidate portfolio also includes PancAlert, an early-stage pancreatic cancer screening test based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples. To learn more, visit mainzbiomed.com or follow us on LinkedIn, Twitter and Facebook.
For media inquiries
MC Services AG
Anne Hennecke/ Simone Neeten
+49 211 529252 20
mainzbiomed@mc-services.eu
For investor inquiries, please contact ir@mainzbiomed.com
Forward-Looking Statements
Certain statements made in this press release are “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as “anticipate”, “believe”, “expect”, “estimate”, “plan”, “outlook”, and “project” and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements reflect the current analysis of existing information and are subject to various risks and uncertainties. As a result, caution must be exercised in relying on forward-looking statements. Due to known and unknown risks, actual results may differ materially from the Company’s expectations or projections. The following factors, among others, could cause actual results to differ materially from those described in these forward-looking statements: (i) the failure to meet projected development and related targets; (ii) changes in applicable laws or regulations; (iii) the effect of the COVID-19 pandemic on the Company and its current or intended markets; and (iv) other risks and uncertainties described herein, as well as those risks and uncertainties discussed from time to time in other reports and other public filings with the Securities and Exchange Commission (the “SEC”) by the Company. Additional information concerning these and other factors that may impact the Company’s expectations and projections can be found in its initial filings with the SEC, including its annual report on Form 20-F filed on April 9, 2024. The Company’s SEC filings are available publicly on the SEC’s website at www.sec.gov. Any forward-looking statement made by us in this press release is based only on information currently available to Mainz Biomed and speaks only as of the date on which it is made. Mainz Biomed undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise, except as required by law.
FAQ
When did Mainz Biomed (MYNZ) regain Nasdaq compliance in 2025?
Which Nasdaq listing requirements did MYNZ meet in 2025?
Will MYNZ continue trading on Nasdaq after regaining compliance?
What is the significance of MYNZ regaining Nasdaq compliance for investors?
